India’s first mRNA-based Covid-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for phase 2/3 clinical trails, the department of biotechnology (DBT) said on Tuesday.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/2Whmx2a
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Gennova vax gets nod for ph 2/3 trials
https://ift.tt/eA8V8J
No comments:
Post a Comment